The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(2R,3R,3aS,6S,6aR)-6-((2-amino-3-bromoquinolin-7-yl)methyl)-2-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)hexahydro-2H-cyclopenta[b]furan-3,3a-diol ID: ALA4849067
PubChem CID: 156503379
Max Phase: Preclinical
Molecular Formula: C26H26BrN5O3
Molecular Weight: 536.43
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Nc1nc2cc(C[C@@H]3CC[C@@]4(O)[C@@H]3O[C@@H](n3ccc5c(C6CC6)ncnc53)[C@@H]4O)ccc2cc1Br
Standard InChI: InChI=1S/C26H26BrN5O3/c27-18-11-15-2-1-13(10-19(15)31-23(18)28)9-16-5-7-26(34)21(33)25(35-22(16)26)32-8-6-17-20(14-3-4-14)29-12-30-24(17)32/h1-2,6,8,10-12,14,16,21-22,25,33-34H,3-5,7,9H2,(H2,28,31)/t16-,21-,22+,25+,26-/m0/s1
Standard InChI Key: URRMKEZGOVGAJV-CSFAFAEBSA-N
Molfile:
RDKit 2D
36 42 0 0 0 0 0 0 0 0999 V2000
40.1475 -25.0838 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
40.9573 -24.0369 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.1744 -24.2682 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.4184 -24.7147 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.9176 -25.3556 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.2224 -26.1077 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.0278 -26.2201 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.5274 -25.5743 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.2199 -24.8247 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.4727 -25.5447 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.7084 -25.2682 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
39.4541 -26.3600 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.6700 -26.5899 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.2146 -25.9156 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.4326 -26.1403 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.4046 -26.9535 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.1693 -27.2313 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.1026 -26.8572 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
39.0725 -27.2934 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
36.7884 -25.6375 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.0309 -25.9440 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.3878 -25.4384 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.6309 -25.7443 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.9205 -26.7491 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1661 -27.0577 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.5204 -26.5527 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.7623 -26.8595 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.6486 -27.6711 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.2992 -28.1750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.0548 -27.8654 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.8917 -27.9791 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
34.1892 -28.9848 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.7202 -24.1786 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.4726 -23.8693 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.8265 -23.3690 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.9994 -25.1224 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0
1 5 1 0
4 2 1 0
2 3 2 0
3 1 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
10 1 1 1
10 11 1 0
11 14 1 0
13 12 1 0
12 10 1 0
13 14 1 0
14 15 1 0
15 16 1 0
16 17 1 0
17 13 1 0
12 18 1 6
13 19 1 6
15 20 1 1
20 21 1 0
21 22 2 0
22 23 1 0
23 26 2 0
25 24 2 0
24 21 1 0
25 26 1 0
26 27 1 0
27 28 2 0
28 29 1 0
29 30 2 0
30 25 1 0
28 31 1 0
29 32 1 0
9 33 1 0
34 33 1 0
35 34 1 0
33 35 1 0
14 36 1 6
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 536.43Molecular Weight (Monoisotopic): 535.1219AlogP: 3.84#Rotatable Bonds: 4Polar Surface Area: 119.31Molecular Species: NEUTRALHBA: 8HBD: 3#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 1CX Acidic pKa: 12.28CX Basic pKa: 5.27CX LogP: 3.97CX LogD: 3.96Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.36Np Likeness Score: 0.52
References 1. Quiroz RV, Reutershan MH, Schneider SE, Sloman D, Lacey BM, Swalm BM, Yeung CS, Gibeau C, Spellman DS, Rankic DA, Chen D, Witter D, Linn D, Munsell E, Feng G, Xu H, Hughes JME, Lim J, Saurí J, Geddes K, Wan M, Mansueto MS, Follmer NE, Fier PS, Siliphaivanh P, Daublain P, Palte RL, Hayes RP, Lee S, Kawamura S, Silverman S, Sanyal S, Henderson TJ, Ye Y, Gao Y, Nicholson B, Machacek MR.. (2021) The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer., 64 (7.0): [PMID:33755451 ] [10.1021/acs.jmedchem.0c02083 ]